Performance adjusted risks: A method to improve the quality of algorithm performance while allowing all to play

Prenatal Diagnosis

Volumn 31, Issue 8, 2011, Pages 797-801

  Evans, Mark I ^a   Cuckle, Howard S ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Columbia University School of Medicine ^*  (United States)

Author keywords

Accuracy; Down syndrome; Nuchal translucency; Precision; Risk

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; GENETIC ALGORITHM; HUMAN; PERFORMANCE ADJUSTED RISK; PREGNANCY; PRIORITY JOURNAL; RISK; TASK PERFORMANCE;

ALGORITHMS; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROCESS ASSESSMENT (HEALTH CARE); RISK ASSESSMENT;

EID: 79960555638     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2769     Document Type: Article

References (24)

1. Cohen AB, Hanft RS. 2004. Technology in American Health Care: Policy Directions for Effective Evaluation and Management. University of Michigan Press: Ann Arbor, MI.
2. Cuckle HS. 1995. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 15: 1057-1065.
3. Cuckle HS. 2003. Updated modeling parameters for Down syndrome screening. Balkan J Med Genet 6:(Suppl 2-3): 101-107.
4. Cuckle HS. 2010. Monitoring quality control of nuchal translucency. Clin Lab Med 30: 593-604.
5. Cuckle H, Benn P. 2010. Multianalyte maternal serum screening for chromosomal defects. In Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment (6th edn), Milunsky A, Milunsky JM (eds). Johns Hopkins University Press: Baltimore; 771-818.
6. Cuckle HS, van Lith JMM. 1999. Appropriate biochemical parameters in first trimester screening for Down's syndrome. Prenat Diagn 19(6): 505-512.
7. Ekelund CK, Jørgensen FS, Petersen OB, Sundberg K, Tabor A. 2008. Danish Fetal Medicine Research Group. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. Br Med J 337: a2547.
8. Evans MI, Cuckle HS. 2007. Biochemical screening for aneuploidy. Expert Rev Obstet Gynecol 2: 765-774.
9. Evans M, Cuckle H. 2008. Do a couple of percentage points actually matter? Am J Obstet Gynecol 201(6):(Suppl 1): S165.
10. Evans MI, Hanft RS. 1997. The introduction of new technologies. ACOG Clin Sem 2(5): 1-3.
11. Evans M, Krantz D, Hallahan T, Sherwin J. 2009. Skewed to the left: under-measurement of NT's and implications for screening efficiency. Am J Obstet Gynecol 201(6):(Suppl 1): S140.
12. Evans MI, Krantz DA, Hallahan TW, Galen RS. 2007a. Meta-analysis of first trimester Down syndrome screening studies: free β human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 196: 198-205.
13. Evans MI, Van Decruyes H, Nicolaides KH. 2007b. Nuchal translucency measurements for first trimester screening: the 'price' of inaccuracy. Fetal Diag Ther 22: 401-404.
14. Evans MI, Pergament E. 2010. Impact of quality of nuchal translucency measurements on detection rates of Trisomies 13 and 18. Fetal DiagnTher 27: 68-71.
15. Galen RS, Gambino SR. 1975. Beyond Normality: the Predictive Value and Efficiency of Medical Diagnosis. Wiley: New York.
16. Logghe H, Cuckle H, Sehmi I. 2003. Centre-specific ultrasound nuchal translucency medians needed for Down's syndrome screening. Prenat Diagn 23: 389-392.
17. Malone FD, Canick JA, Ball RH, et al. 2005. First trimester or second trimester screening, or both, for Down syndrome. N Engl J Med 353: 2068-2070.
18. Nicolaides KH, Snijders RJM, Cuckle HS. 1998. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 18(5): 519-523.
19. Palomaki GE, Lee JE, Canick JA, McDowell GA, Donnenfeld AE, ACMG Laboratory Quality Assurance Committee. 2009. Technical standards and guidelines: prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. Genet Med 11: 669-681.
20. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre projection assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125): 343-346.
21. Snijders RJ, Thom EA, Zachary JM, et al. 2002. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 19(4): 353-359.
22. Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH. 2003. Delta-NT or NT MoM, which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22: 142-148.
23. Wapner RJ, Thom E, Simpson JL, et al. 2003. First trimester serum biochemistry and fetal nuchal translucency screening (BUN) study group: first trimester nuchal translucency for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
24. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. 2008. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31: 376-383.